Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Izrael2. fázis

Biosignature of the Response to Treatment With Cannabis Oil in Individuals With Fibromyalgia

A legfontosabb adatok

Ki végzi
Rambam Health Care Campus
Hol
Haifa (Izrael)A helyszín megnézése
Azonosító
Állapot
Toboroz
Fázis
2. fázis
Résztvevők
150 fő, tervezett
Kezdés
2024. máj. 30.
Várható befejezés
2027. máj.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • Cannabis Oil (5% THC/5% CBD)
  • Sham Cannabis Oil
A regiszteradat frissítve
2025. április 27.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults aged 30 and over with fibromyalgia who still have pain despite standard care. They will get cannabis oil or a placebo oil.

Életkor
30 years and over
Nem
Men and women
A betegség stádiuma
Fibromyalgia confirmed by a pain specialist using the 2016 criteria, with symptoms for 12 months or more. Average pain of 6 or more in the past week.
Korábbi kezelés
Still having symptoms despite standard care, including pain medicines, anti-depressants (tricyclic and SNRI) and anti-epileptic medicines. The treating doctor must judge that cannabis can be used. No cannabis use in the past month.

A részvétel fő kizáró okai

  • Cannabis use in the past month
  • Personal or family history of psychotic disorders, or current or past anxiety disorder
  • Current or past substance addiction or abuse
  • Heart or blood vessel disease, epilepsy or seizures, active liver disease, or inflammatory bowel disease
  • Pregnancy, breastfeeding or plans to become pregnant

A regiszter feltételei, szó szerint

Mind a 19 feltétel megnézéseKevesebb

Ki vehet részt

  • Adult men and women aged 30 years and over
  • Diagnosis of fibromyalgia confirmed according to the 2016 diagnostic criteria by a pain specialist, with relevant symptoms lasting 12 months or more
  • An average reported pain ≥ 6 during the preceding week
  • Eligible for cannabis at the discretion of the treating physician
  • Has remained symptomatic despite receiving standard care for fibromyalgia including analgesics, anti-depressants (tricyclic and SNRI) and anti-epileptic agents

Ki nem vehet részt

  • Any significant comorbid condition at the discretion of the PI (e.g. inflammatory arthritis, inflammatory bowel disease, cancer)
  • Personal or family history of psychotic disorders
  • Current or past anxiety disorder
  • Any uncontrolled psychiatric pathology
  • Current or history of substance addiction or abuse
  • Diagnosed dementia or cognitive impairment
  • Personal history of cardiovascular disease
  • Known allergy to any of the cannabis oil ingredients
  • Patients with a history of seizure disorder (excluding childhood febrile convulsions) or epilepsy
  • Active liver disease
  • Inflammatory Bowel Disease (IBD)
  • Patients who have used cannabis during the preceding month
  • Pregnancy, lactation or intention to conceive
  • Any contraindication to the use of MC

Ez a vizsgálat jelenleg itt érhető el: Izrael.

  • Rambam Health Care CampusHaifa, IzraelContact: May Haddad, PhDRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

Fibromyalgia is a chronic condition that causes widespread pain, fatigue, and other symptoms, significantly affecting quality of life. Unfortunately, there are few effective treatments available. Recently, medical cannabis has gained attention as a potential treatment, leading many countries to approve its use for fibromyalgia. However, its success is limited-only about 25% of patients experience meaningful pain relief, and side effects like dizziness or fatigue are common. Not everyone responds to medical cannabis the same way, and researchers think this variability may partly be explained by differences in the gut microbiome-the community of bacteria and other microorganisms living in our digestive system. These microbes are known to influence various aspects of health, including pain and how the body processes medications. Our research focuses on understanding the link between the gut microbiome and fibromyalgia. We propose a study where 150 fibromyalgia patients will be treated with either cannabis oil or a placebo in a double-blind trial. By analyzing their symptoms and gut microbiome, we hope to identify patterns that could predict who will benefit most from cannabis treatment. If successful, this research could lead to more personalized and effective treatment options for fibromyalgia.

A vizsgálat 2 csoportja

  • Active Comparator: Cannabis Oil (5% THC/5% CBD)Már használt kezelés, összehasonlításként

    Participants in this arm will receive cannabis oil containing a balanced formulation of 5% THC and 5% CBD. The intervention will span three months, including a six-week titration period to optimize dosing, followed by a maintenance phase. Doses will be self-administered sublingually and adjusted based on individual tolerance and efficacy. Comprehensive assessments will monitor clinical outcomes, gut microbiome composition, and circulating metabolomics to explore correlations with treatment response and safety. This arm will comprise 120 patients.

    Kezelés: Cannabis Oil (5% THC/5% CBD)

  • Sham Comparator: Placebo OilSzínlelt kezelés, összehasonlításként

    Participants in this arm will receive placebo oil, which is visually and chemically matched to the active cannabis oil but contains no active cannabinoids (THC or CBD). Like the active arm, participants will undergo a three-month intervention, including a six-week titration period and maintenance phase. Outcomes, including clinical measures and biological analyses, will be used as a control to evaluate the therapeutic effects of the cannabis oil. This arm will comprise 30 patients.

    Kezelés: Sham Cannabis Oil

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
A regiszteradat frissítve
2025. április 27.